Nearly all disease will become treatable in our lifetimes. At the same time, drug discovery is quickly becoming an engineering discipline. There has never been a more exciting time for new biotech research to solve humanity’s most fundamental problems.

At Mandolin, we’re building the “last mile” delivery infrastructure to accelerate this unbounded future of cutting-edge drugs — cell/gene therapies and biologics for Alzheimer’s, cancer, schizophrenia, genetic disorders, amongst many others. Reasoning-adept LLMs uniquely unlock the opportunity to bridge this market gap. We’re starting with an “AI knowledge worker” for clinics administering these drugs, and then partnering with health insurers and pharma companies to bring drug breakthroughs to market at scale.

Ultimately, our mission is to substantial extend all healthy human lifespans by minimizing the time to bring life-changing drugs to patients.

We’re a lean, aggressive team of former founders set on building a new generational incumbent in healthcare. We’ve raised substantial institutional funding from the best healthcare AI investors from firms like SignalFire, Maverick, and Thrive (including first institutional checks into rocketships like Hims&Hers, Ro, Grow Therapy, Cityblock, and Devoted Health).